Announcements
Sidley Represents Sole Source in Acquisition of Cybersecurity Provider Brite
January 12, 2026
Sidley represented Sole Source Capital LLC, a private equity firm that invests in industrial and business services sectors, in its acquisition of Brite, a cybersecurity and managed services provider headquartered in New York. The transaction represents Sole Source Capital LLC’s first platform investment from its third fund, SSC Partners Fund III, and expands its presence into the cybersecurity and IT services sectors.
The Sidley team was led by Germaine Gurr (M&A and Private Equity), and included Victoria Richmond, Kristin Smith, Fiona Winicki, and Celine Ang (M&A and Private Equity); Jonathan Wilan and David Lashway (Privacy and Cybersecurity); Tara Lancaster (Tax); Lauren Gallagher, Alexandra Peterson, and Lindsay Fisher-McFarland (Employee Benefits and Executive Compensation); Katherine Roberts and Beth Scheel (Labor, Employment and Immigration); and Scott Goldstein (Insurance).
The Sidley team was led by Germaine Gurr (M&A and Private Equity), and included Victoria Richmond, Kristin Smith, Fiona Winicki, and Celine Ang (M&A and Private Equity); Jonathan Wilan and David Lashway (Privacy and Cybersecurity); Tara Lancaster (Tax); Lauren Gallagher, Alexandra Peterson, and Lindsay Fisher-McFarland (Employee Benefits and Executive Compensation); Katherine Roberts and Beth Scheel (Labor, Employment and Immigration); and Scott Goldstein (Insurance).
連絡先
得意分野
Suggested News & Insights
Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027Sidley at Solana Breakpoint 2026Sunday, November 15, 2026 - Tuesday, November 17, 2026Be Careful What You Bargain For: Court of Chancery Holds Startup to “Binding” Term Sheet and Orders Transfer of Its IPNovember 11, 2026Private Equity Partner Jonathan Stott Joins Sidley’s Office in San FranciscoNovember 11, 2026Sidley Represents Mubadala Capital in Its Strategic Minority Investment in LSV AdvisorsNovember 11, 2026Sidley Represents Sino Biopharmaceutical in its US$7 Billion Licensing Agreement With Boehringer IngelheimNovember 9, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory





